Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03098953 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations
A Phase 1 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03098953 is a Phase 1 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 15 participants.
The verdict
NCT03098953, a Phase 1 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel
Interventions
- DRUG Loteprednol Etabonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-04-10 |
| Est. Completion | 2017-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03098953
The ClinicalTrials.gov registry entry for NCT03098953 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Loteprednol Etabonate is the first listed.
NCT03098953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03098953 about?
NCT03098953 is a clinical study titled "Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations". Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel
What is the current status of trial NCT03098953?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2017-04-10. Estimated completion is 2017-05-12.
What interventions are being tested in trial NCT03098953?
The interventions under investigation include: Loteprednol Etabonate (DRUG).
Who is sponsoring clinical trial NCT03098953?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.